ArticleCancer medicine2026
Adjusted Risk Stratification of Indeterminate Thyroid Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe TI-RADS guides the initial management of thyroid nodules, but the malignancy risk across different categories of cytologically indeterminate thyroid nodules (CITNs), particularly AUS and FN, remains unclear.
methodsWe reviewed thyroid FNA specimens diagnosed as AUS or FN with TI-RADS scores of 3, 4, or 5 from 2017 to 2025. Clinical data, molecular results, and surgical outcomes were analyzed.
resultsA total of 919 CITNs were identified: 304 with TI-RADS 3, 454 with TI-RADS 4, and 161 with TI-RADS 5. In the absence of molecular alterations, the risk of malignancy (ROM) was low for AUS and FN in both TI-RADS 3 and 4 categories (< 10%). In contrast, TI-RADS 5 nodules diagnosed as AUS or FN had the highest ROM (56%). ROM similarly increased with the TI-RADS score. For AUS, ROM was 14% (TI-RADS 3), 31% (TI-RADS 4), and 60% (TI-RADS 5). For FN, ROM increased from 26% to 44% to 57% across TI-RADS 3, 4, and 5, respectively. Notably, even AUS nodules without detectable mutations had a high ROM of 44% in TI-RADS 5, compared to 10% and 15% in TI-RADS 3 and 4, respectively.
conclusionOur findings demonstrate distinctive ROMs among AUS and FN stratified by TI-RADS category and underscore the variable utility of molecular testing. TI-RADS 5 CITNs carry a significantly higher ROM even in the absence of molecular alterations, suggesting the importance of combining TI-RADS and TBSRTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.